Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Nathaniel Liddy"'
Autor:
Andrew Poole, Vijaykumar Karuppiah, Annabelle Hartt, Jaafar N. Haidar, Sylvie Moureau, Tomasz Dobrzycki, Conor Hayes, Christopher Rowley, Jorge Dias, Stephen Harper, Keir Barnbrook, Miriam Hock, Charlotte Coles, Wei Yang, Milos Aleksic, Aimee Bence Lin, Ross Robinson, Joe D. Dukes, Nathaniel Liddy, Marc Van der Kamp, Gregory D. Plowman, Annelise Vuidepot, David K. Cole, Andrew D. Whale, Chandramouli Chillakuri
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Cancers often harbor mutations in genes encoding important regulatory proteins, but therapeutic targeting of these molecules proves difficult due to their high structural similarity to their non-mutated counterpart. Here authors show the engineering
Externí odkaz:
https://doaj.org/article/d2f84672e7fe4eb3b7df368784cf9d36
Autor:
Andrew, Poole, Vijaykumar, Karuppiah, Annabelle, Hartt, Jaafar N, Haidar, Sylvie, Moureau, Tomasz, Dobrzycki, Conor, Hayes, Christopher, Rowley, Jorge, Dias, Stephen, Harper, Keir, Barnbrook, Miriam, Hock, Charlotte, Coles, Wei, Yang, Milos, Aleksic, Aimee Bence, Lin, Ross, Robinson, Joe D, Dukes, Nathaniel, Liddy, Marc, Van der Kamp, Gregory D, Plowman, Annelise, Vuidepot, David K, Cole, Andrew D, Whale, Chandramouli, Chillakuri
Publikováno v:
Nature communications. 13(1)
Neoantigens derived from somatic mutations are specific to cancer cells and are ideal targets for cancer immunotherapy. KRAS is the most frequently mutated oncogene and drives the pathogenesis of several cancers. Here we show the identification and d
Autor:
Malkit Sami, Ben de Wet, Elizabeth A. Potter, Rory M. Crean, Katy A. Lloyd, Velupillai Srikannathasan, Nikolai Lissin, Milos Aleksic, Anitha Jeyanthan, Miriam Hock, David K. Cole, Peter Eamon Molloy, Pierre J. Rizkallah, Marco Lepore, Annelise Vuidepot, Christopher J. Holland, Brian Cameron, Thomas Blicher, Robert J. Pengelly, Christopher R. Pudney, Ross A. Robinson, Johanne M. Pentier, Thomas E. Spinner, Marc W. van der Kamp, Bent K. Jakobsen, Nathaniel Liddy, Paul J. Conroy, Stephen Harper, Angharad Lloyd
Publikováno v:
J Clin Invest
Tumor-associated peptide-human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface-expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that incorporate an an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cbe9e3e9f83c5de1920113bed8d5316
https://europepmc.org/articles/PMC7190993/
https://europepmc.org/articles/PMC7190993/
Autor:
Andrew James Godkin, Florian Madura, Andrew K. Sewell, David K. Cole, Jade R. Hopkins, Nathaniel Liddy, Anna Marta Bulek, Andrew Trimby, E. Joel Loveridge, Andrea J. A. Schauenburg, Pierre J. Rizkallah, Bent K. Jakobsen, Stephen A. Wells, Anna Fuller, John J. Miles, Mateusz Legut, Malkit Sami, Christopher J. Holland, Yi Li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05af3d7484dbdca54fcaedb0db319f63
https://doi.org/10.1002/eji.201948085/v2/response1
https://doi.org/10.1002/eji.201948085/v2/response1
Autor:
Florian, Madura, Pierre J, Rizkallah, Mateusz, Legut, Christopher J, Holland, Anna, Fuller, Anna, Bulek, Andrea J, Schauenburg, Andrew, Trimby, Jade R, Hopkins, Stephen A, Wells, Andrew, Godkin, John J, Miles, Malkit, Sami, Yi, Li, Nathaniel, Liddy, Bent K, Jakobsen, E Joel, Loveridge, David K, Cole, Andrew K, Sewell
Publikováno v:
European Journal of Immunology
The HLA‐A*02:01‐restricted decapeptide EAAGIGILTV, derived from melanoma antigen recognized by T‐cells‐1 (MART‐1) protein, represents one of the best‐studied tumor associated T‐cell epitopes, but clinical results targeting this peptide
Autor:
Namir J. Hassan, Joseph Dukes, Andrew M.F. Johnson, Annelise Vuidepot, Jane Harper, Brian Cameron, Emma Baston, Peter Eamon Molloy, Giovanna Bossi, C. Coughlin, Nathaniel Liddy, Malkit Sami, Tara Mahon, Bent K. Jakobsen, A. Powesland, Samantha Paston, L. Holt
Publikováno v:
European Journal of Cancer. 92:S15-S16
Autor:
Bent K. Jakobsen, Nicole Mai, Nathaniel Liddy, Annelise Vuidepot, Andrew Preston, Izabela Bombik, Alessio Bortoluzzi
Publikováno v:
Cancer Immunology Research. 7:B001-B001
Immunotherapeutic strategies are centered on harnessing the human immune system to recognise and destroy cancer cells. At Immunocore, we have developed bi-specific Immune-mobilising monoclonal TCRs Against Cancer (ImmTAC) molecules comprising a solub
Autor:
Kim M. Miles, Bent K. Jakobsen, Anna Marta Bulek, Yi Li, Moushumi Hossain, Andrew K. Sewell, Malkit Sami, Brian M. Baker, Anna Fuller, Pierre J. Rizkallah, Nathaniel Liddy, Andrea J. A. Schauenburg, Christopher J. Holland, John J. Miles, David K. Cole, Florian Madura
Publikováno v:
The Journal of Biological Chemistry
Background: The molecular principles governing T-cell specificity are poorly understood. Results: High affinity binding of a melanoma-specific T-cell receptor (TCR) is mediated through new MHC contacts and distinct thermodynamics. Conclusion: A novel
Autor:
Milos Aleksic, Nick Pumphrey, Annelise Vuidepot, Nathaniel Liddy, Kyong-Mi Chang, Peter Eamon Molloy, Bent K. Jakobsen
Publikováno v:
European Journal of Immunology. 42:3174-3179
T-cell destiny during thymic selection depends on the affinity of the TCR for autologous peptide ligands presented in the context of MHC molecules. This is a delicately balanced process; robust binding leads to negative selection, yet some affinity f
Autor:
Jessie Gavarret, Katherine Adams, Jane Harper, Bent K. Jakobsen, Yi Li, Frayne Bianchi, Emma Baston, Michael Kalos, Penio Todorov, Malkit Sami, Steve M. Dunn, Emma Gostick, Nikolai Lissin, David Price, Rebecca Dennis, Peter Eamon Molloy, Samantha Paston, Gabriela Plesa, Kristin Ladell, Giovanna Bossi, Namir J. Hassan, Deborah H. Sutton, Naomi Harwood, Annelise Vuidepot, Carl H. June, Nicholas J. Pumphrey, Nathaniel Liddy, Yvonne McGrath, Brian Cameron, Daniel Williams, Andrew K. Sewell, Tara Mahon, Rebecca Ashfield, Anna Lissina, Andrew M.F. Johnson
Publikováno v:
Nature Medicine. 18:980-987
T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a minority of patients with cancer. In the majority of these individuals, however, there is a failure of the specific T cell receptor (TCR)–mediated immune